MedTrace Logo

Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain

NCT00170898 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 419

Last updated 2006-10-13

No results posted yet for this study

Summary

This study is designed to develop our understanding of the risk-benefit of using lumiracoxib in patients with acute musculoskeletal pain due to uncomplicated soft tissue injury.

Conditions

Interventions

DRUG

Lumiracoxib

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals UK Limited Novartis Pharmaceuticals UK Limited · Novartis Pharmaceuticals UK Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00170898 on ClinicalTrials.gov